A spokesperson for the National Parks and Wildlife Service said while data collected so far has not yet been analysed, there ...

Good morning, everyone, and welcome, everyone, to the Prelude Therapeutics Investor Conference Call. Today's call is being recorded and is expected to last up to 45 minutes. At this time, I will now ...

This trial represents the first major advancement in second-line GIST treatment in over two decades, potentially transforming the therapeutic landscape. Cogent Biosciences announced positive results ...

A flu strain that emerged over the summer is causing "unprecedented" outbreaks in Japan, as well as in Canada and the U.K.

Effective management of inherited retinal diseases requires a comprehensive approach to diagnosis and treatment, according to ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...

Only one in every six million people have the Rh null blood type. Now researchers are trying to grow it in the laboratory in ...

Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026New preclinical data demonstrated SIL204’s ...

Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as ...

Received $54.6 Million in Gross Proceeds from Warrant Exercises: In September and October 2025, SELLAS received a total of approximately $54.6 million in gross proceeds from the immediate exercise of ...